You are here
- Home
- Diseases & Conditions
- All Diseases and Conditions
An Open Label, Multicentre, Single Arm Study to Characterise the Efficacy, Safety and Tolerability of Gefitinib 250 mg (IRESSA™) as First Line Treatment in Caucasian Patients, Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Disease
- non-small cell lung cancer
- Drug Name
- IRESSA
- Generic Name
- Gefitinib
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- IV
- Start Date
- Sep 8, 2010
- Study Name
- D791AC00014
- Study Id
- D791AC00014
- ClinicalTrials.gov ID
- NCT01203917
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
